West Pharmaceutical Services, Inc. (WST) Tops Q1 EPS by 16c; Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $392.15 -0.48%
EPS Growth %: +12.2%
Financial Fact:
Cost of goods and services sold: 255.6M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +12.2%
Financial Fact:
Cost of goods and services sold: 255.6M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q1 EPS of $0.81, $0.16 better than the analyst estimate of $0.65. Revenue for the quarter came in at $316.3 million versus the consensus estimate of $308.2 million.
West Pharmaceutical Services, Inc. sees FY2012 EPS of $2.50-$2.67, versus prior guidance of $2.37-$2.55 and the consensus of $2.49. West Pharmaceutical Services, Inc. sees FY2012 revenue of $1.25-$1.28 billion, versus prior guidance of $1.215-$1.245 billion and the consensus of $1.23 billion.
For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.
West Pharmaceutical Services, Inc. sees FY2012 EPS of $2.50-$2.67, versus prior guidance of $2.37-$2.55 and the consensus of $2.49. West Pharmaceutical Services, Inc. sees FY2012 revenue of $1.25-$1.28 billion, versus prior guidance of $1.215-$1.245 billion and the consensus of $1.23 billion.
For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
